A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program

Anurag Verma, Noah L. Tsao, Lauren O. Thomann, Yuk‐Lam Ho, Sudha K. Iyengar, Shiuh‐Wen Luoh, Rotonya M. Carr, Dana C. Crawford, Jimmy T. Efird, Jennifer E. Huffman, Adriana M. Hung, Kerry L. Ivey, Michael G. Levin, Julie A. Lynch, Pradeep Natarajan, Saiju Pyarajan, Alexander G. Bick, Lauren Costa, Giulio Genovese, Richard L. Hauger, Ravi Madduri, Gita A. Pathak, Renato Polimanti, Benjamin F. Voight, Marijana Vujković, Maryam Zekavat, Hongyu Zhao, Marylyn D. Ritchie, Kyong‐Mi Chang, Kelly Cho, Juan P. Casas, Philip S. Tsao, J. Michael Gaziano, Christopher J. O’Donnell, Scott M. Damrauer, Katherine P. LiaomedRxiv 2021 · DOI

Abstract

The study aims to determine the shared genetic architecture between COVID-19 severity and existing medical conditions using electronic health record (EHR) data. We conducted a Phenome-Wide Association Study (PheWAS) of genetic variants associated with critical illness (n=35) or hospitalization (n=42) due to severe COVID-19 using genome-wide association summary data from the Host Genetics Initiative. PheWAS analysis was performed using genotype-phenotype data from the Veterans Affairs Million Veteran Program (MVP). Phenotypes were defined by International Classification of Diseases (ICD) codes mapped to 1,559 clinically relevant groups. Among 658,582 Veterans, variants at the ABO locus (rs495828, rs505922) associated with the largest number of phenotypes, specifically venous embolism and thrombosis. Among respiratory conditions, the MUC5B locus (rs35705950) was linked to idiopathic fibrosing alveolitis, while the TYK2 locus (rs11085727) associated with reduced risk for autoimmune conditions like psoriasis and lupus. PheWAS stratified by genetic ancestry demonstrated differences, such as the LMNA (rs581342) association with neutropenia in Veterans of African ancestry. Overall, we observed a shared genetic architecture between COVID-19 severity and underlying risk factors, highlighting the fine balance of immune host response and autoimmunity.

Introduction

While clinical risk factors for COVID-19—such as age, obesity, and diabetes—are well-documented, the underlying genetic architecture that links the virus to these comorbidities remains a critical area of inquiry. Most genetic studies focus on identifying risk genes for a single disease. This study utilizes a Phenome-Wide Association Study (PheWAS) to flip the script: it examines genetic variants already known to be associated with severe COVID-19 and asks what other clinical conditions these genes influence. By mapping this shared genetic "wiring," researchers can better understand the biological mechanisms of the disease and identify potential drug targets or risks for specific patient populations.

Methods and Datasets

The researchers leveraged the Million Veteran Program (MVP), one of the world’s largest and most diverse biobanks, containing genotype and Electronic Health Record (EHR) data from 658,582 US Veterans. This cohort is particularly valuable for its significant representation of African, Hispanic, and Asian populations.

The PheWAS Approach

Unlike a standard Genome-Wide Association Study (GWAS) that looks at one disease across many genes, a PheWAS looks at specific genetic variants (SNPs) across a vast "phenome" of thousands of different clinical conditions.

  1. Variant Selection: 45 lead variants associated with "critical COVID" and 42 associated with "hospitalized COVID" were sourced from the international COVID-19 Host Genetics Initiative (Release v6).
  2. Phenotype Mapping: Researchers used "phecodes" to group thousands of ICD-9 and ICD-10 hospital diagnosis codes into 1,559 clinically meaningful categories.
  3. Statistical Analysis: Logistic and Firth regression were used to test associations, adjusting for age, sex, and genetic ancestry, followed by a trans-ethnic meta-analysis.

Key Insights

The Coagulation Connection

Variants at the ABO locus, which determines blood type, showed the strongest and most frequent associations, accounting for approximately 35-37% of all significant phenotype hits. These variants (rs495828, rs505922) were heavily linked to "hypercoagulable states" such as venous embolism and thrombosis. This provides a robust genetic basis for why blood clotting is a hallmark of severe COVID-19 cases.

The Immune Balancing Act

A variant in the TYK2 gene (rs11085727) revealed a fascinating biological trade-off. This variant is known to reduce the risk of autoimmune diseases like psoriasis (OR 0.88) and lupus (OR 0.84) by dampening certain immune signals. However, the study found that this same dampening effect appears to hinder the body’s ability to fight off severe COVID-19. This highlights the "fine balance" required in the host immune response: treatments that target inflammation must be carefully weighed against the risk of impairing viral defense.

Lung Disease Overlap

The study identified a significant overlap between COVID-19 severity and Idiopathic Pulmonary Fibrosis (IPF). Specifically, the MUC5B locus (rs35705950) was associated with a nearly three-fold increase in the risk of idiopathic fibrosing alveolitis (OR 2.83). This suggests that the pathways leading to chronic lung scarring may also predispose individuals to acute respiratory failure during a viral infection.

Ancestry-Specific Risks

By stratifying results by genetic ancestry, the researchers discovered that certain risks are not universal. A variant in the LMNA gene (rs581342) was strongly associated with neutropenia (low white blood cell count) specifically in Veterans of African ancestry (OR 1.29), but this association was not significant in the European cohort. Such findings emphasize the importance of diverse datasets in understanding heterogeneous clinical outcomes.

Conclusion and Clinical Implications

This PheWAS demonstrates that the genetic risk for severe COVID-19 is deeply intertwined with the genetics of blood clotting, chronic lung disease, and immune regulation. These results provide a cautionary note for clinicians: when considering treatments like JAK inhibitors that target immune pathways, it is vital to recognize that modulating the immune system to treat inflammation might inadvertently hinder the body's natural defense against the virus. Future work will continue to explore these shared pathways to refine therapeutic strategies and risk stratification.

Summary updated

Abstract

The study aims to determine the shared genetic architecture between COVID-19 severity with existing medical conditions using electronic health record (EHR) data. We conducted a Phenome-Wide Association Study (PheWAS) of genetic variants associated with critical illness (n=35) or hospitalization (n=42) due to severe COVID-19 using genome-wide association summary from the Host Genetics Initiative. PheWAS analysis was performed using genotype-phenotype data from the Veterans Affairs Million Veteran Program (MVP). Phenotypes were defined by International Classification of Diseases (ICD) codes mapped to clinically relevant groups using published PheWAS methods. Among 658,582 Veterans, variants associated with severe COVID-19 were tested for association across 1,559 phenotypes. Variants at the <i>ABO</i> locus (rs495828, rs505922) associated with the largest number of phenotypes (n<sub>rs495828</sub>=53 and n<sub>rs505922</sub>=59); strongest association with venous embolism, odds ratio (ORrs495828 1.33 (p=1.32 × 10<sup>-199</sup>), and thrombosis OR<sub>rs505922</sub> 1.33, p=2.2 × 10<sup>-265</sup>. Among 67 respiratory conditions tested, 11 had significant associations including <i>MUC5B</i> locus (rs35705950) with increased risk of idiopathic fibrosing alveolitis OR 2.83, p=4.12 × 10<sup>-191</sup>; <i>CRHR1 (</i>rs61667602) associated with reduced risk of pulmonary fibrosis, OR 0.84, p=2.26 × 10<sup>-12</sup>. The <i>TYK2</i> locus (rs11085727) associated with reduced risk for autoimmune conditions, e.g., psoriasis OR 0.88, p=6.48 × 10<sup>-23</sup>, lupus OR 0.84, p=3.97 × 10<sup>-06</sup>. PheWAS stratified by genetic ancestry demonstrated differences in genotype-phenotype associations across ancestry. <i>LMNA</i> (rs581342) associated with neutropenia OR 1.29 p=4.1 × 10<sup>-13</sup> among Veterans of African ancestry but not European. Overall, we observed <b>a</b> shared genetic architecture between COVID-19 severity and conditions related to underlying risk factors for severe and poor COVID-19 outcomes. Differing associations between genotype-phenotype across ancestries may inform heterogenous outcomes observed with COVID-19. Divergent associations between risk for severe COVID-19 with autoimmune inflammatory conditions both respiratory and non-respiratory highlights the shared pathways and fine balance of immune host response and autoimmunity and caution required when considering treatment targets.
BibTeX
@misc{verma2021phenome,
  author = {Anurag Verma and Noah L. Tsao and Lauren O. Thomann and Yuk‐Lam Ho and Sudha K. Iyengar and Shiuh‐Wen Luoh and Rotonya M. Carr and Dana C. Crawford and Jimmy T. Efird and Jennifer E. Huffman and Adriana M. Hung and Kerry L. Ivey and Michael G. Levin and Julie A. Lynch and Pradeep Natarajan and Saiju Pyarajan and Alexander G. Bick and Lauren Costa and Giulio Genovese and Richard L. Hauger and Ravi Madduri and Gita A. Pathak and Renato Polimanti and Benjamin F. Voight and Marijana Vujković and Maryam Zekavat and Hongyu Zhao and Marylyn D. Ritchie and Kyong‐Mi Chang and Kelly Cho and Juan P. Casas and Philip S. Tsao and J. Michael Gaziano and Christopher J. O’Donnell and Scott M. Damrauer and Katherine P. Liao and Katherine Liao},
  title = {{A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program}},
  year = {2021},
  doi = {10.1101/2021.05.18.21257396},
  howpublished = {medRxiv},
}
Figure